Evidence map›Paper›PMID 41531951›Full record

ArticleACS medicinal chemistry letters2026

Repositioning a Human Kinase Platelet-Derived Growth Factor Receptor Alpha Type II Inhibitor for Malaria and Inhibition of Hemozoin Formation.

Mmakwena M Mmonwa, Oluwatosin Audu, Keletso Maepa, Godwin A Dziwornu, Preshen Govender, Liso Tshaka, James Burrows, Dale Taylor, Keabetswe Masike, Mathew Njoroge and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mmakwena M MmonwaHolistic Drug Discovery and Development (H3D) Centre, Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.
Oluwatosin AuduHolistic Drug Discovery and Development (H3D) Centre, Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.
Keletso MaepaDepartment of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.
Godwin A DziwornuHolistic Drug Discovery and Development (H3D) Centre, Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.ORCID https://orcid.org/0000-0003-1668-8818
Preshen GovenderHolistic Drug Discovery and Development (H3D) Centre, Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.
Liso TshakaHolistic Drug Discovery and Development (H3D) Centre, Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.
James BurrowsHolistic Drug Discovery and Development (H3D) Centre, Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.
Dale TaylorHolistic Drug Discovery and Development (H3D) Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, Cape Town 7925, South Africa.
Keabetswe MasikeHolistic Drug Discovery and Development (H3D) Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, Cape Town 7925, South Africa.
Mathew NjorogeHolistic Drug Discovery and Development (H3D) Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, Cape Town 7925, South Africa.
Kathryn J WichtHolistic Drug Discovery and Development (H3D) Centre, Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.ORCID https://orcid.org/0000-0001-6145-9956
Lauren B CoulsonHolistic Drug Discovery and Development (H3D) Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, Cape Town 7925, South Africa.ORCID https://orcid.org/0000-0003-4699-0428
Kelly ChibaleHolistic Drug Discovery and Development (H3D) Centre, Department of Chemistry, University of Cape Town, Rondebosch 7701, South Africa.ORCID https://orcid.org/0000-0002-1327-4727

Funding

Repurposing kinase inhibitor chemotypes as antimalarialsR01AI152092 · NIAID · UNIVERSITY OF CAPE TOWN · PI CHIBALE, KELLY, FERRINS, LORI · 2020 to 2024
$1.6M
NIAID NIH HHS R01 AI152092
6 · The paper itself

Abstract

A type II Platelet-Derived Growth Factor Receptor Alpha

Indexed as

HemozoinMalariaPlasmodiumβ-Hematin

Identifiers

PMID41531951
PMCPMC12794062

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.